RLG Notes With Concern a Recent Study Linking Fosamax to Non-Healing Bone Fractures
The possible femur-fracturing side effects of Fosamax have been known for years. But RLG acknowledges with concern a new study from the Journal of Bone & Joint Surgery that further reinforces the link between the drug and fractures that don’t heal. RLG, which represents clients in Fosamax lawsuits, maintains a website that provides a history of the drug and offers information on lawsuits.
The JBJS study looked at Adverse Event Reports from the U.S. Food and Drug Administration from 1996 to 2011 relating to people who have used bisphosphonates such as Fosamax, which is manufactured by Merck and first marketed in 1995. The researchers found that up to 26 percent of published cases of femoral fractures showed delayed healing or no healing at all, according to the study.
“Based on the phone calls the law firm has received about Fosamax, the drug’s bone-fracture problems are one of the key reasons people seek to bring Fosamax lawsuits,” said Rochelle Rottenstein, principal of RLG. “The other is jaw death. Even though this new study doesn’t guarantee monetary compensation for those who file suit, it is important evidence nevertheless.”
Nationwide lawsuits have been divided into two different federal pretrial case consolidations. Cases involving alleged femur fractures are being handled in the U.S. District Court for the District of New Jersey (MDL-2243). Lawsuits related to Fosamax’s alleged jaw death side effects are being handled in the U.S. District Court for the Southern District of New York (MDL-1789).
